Insider · CIK 0001979567
Supurna VedBrat
Files at RDZN (Roadzen Inc.). First filing Dec 15, 2023, latest Sep 3, 2024.
In brief
Supurna VedBrat files SEC Form 4 as director at RDZN (Roadzen Inc.). Since Dec 15, 2023, Supurna VedBrat has reported 4 open-market buys worth $33k and 0 open-market sells worth $0, the latest filed on Sep 3, 2024.
A track record needs three past buys with six months of prices behind them; Supurna VedBrat has 1, so none is measured yet.
The newest scored trade: bought $1,030 of RDZN on Aug 30, 2024, filed Sep 3, 2024, scored 36 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RDZN: Roadzen Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Roadzen Inc. | $1,030 500 shares | +4% | +72% from low-82% from high | |
| 42Moderate | Roadzen Inc. | $4,460 2,000 shares | +21% | +84% from low-81% from high | |
| 34Weak | Roadzen Inc. | $1,853 1,300 shares | +16% | +13% from low-88% from high | |
| 44Moderate | Roadzen Inc. | $26k 8,250 shares | - | +11% from low-73% from high |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2025 | RDZN Roadzen Inc. | AGrant or award Stock Option (right to buy)derivative | +152,732 | $0.00 | $0 | 152,732 | Jan 7, 2026 |
| Aug 30, 2024 | RDZN Roadzen Inc. | POpen-market purchase Ordinary Shares | +500 | $2.06 | $1,030 | 12,050 | Sep 3, 2024 |
| Aug 27, 2024 | RDZN Roadzen Inc. | POpen-market purchase Ordinary Shares | +1,000 | $2.20 | $2,200 | 10,550 | Aug 28, 2024 |
| Aug 27, 2024 | RDZN Roadzen Inc. | POpen-market purchase Ordinary Shares | +1,000 | $2.26 | $2,260 | 11,550 | Aug 28, 2024 |
| Aug 16, 2024 | RDZN Roadzen Inc. | POpen-market purchase Ordinary Shares | +300 | $1.41 | $423 | 8,550 | Aug 21, 2024 |
| Aug 20, 2024 | RDZN Roadzen Inc. | POpen-market purchase Ordinary Shares | +1,000 | $1.43 | $1,430 | 9,550 | Aug 21, 2024 |
| Jun 20, 2024 | RDZN Roadzen Inc. | JOther Warrantsderivative | +50,000 | - | - | 50,000 | Jun 24, 2024 |
| Jan 19, 2024 | RDZN Roadzen Inc. | POpen-market purchase 13% Convertible Debenturesderivative | +500,000 | $500,000.00 | $250B | 500,000 | Jan 23, 2024 |
| Dec 7, 2023 | RDZN Roadzen Inc. | POpen-market purchase Ordinary Shares | +3,150 | $3.20 | $10k | 3,150 | Dec 15, 2023 |
| Dec 8, 2023 | RDZN Roadzen Inc. | POpen-market purchase Ordinary Shares | +3,100 | $3.11 | $9,641 | 6,250 | Dec 15, 2023 |
| Dec 11, 2023 | RDZN Roadzen Inc. | POpen-market purchase Ordinary Shares | +2,000 | $2.91 | $5,820 | 8,250 | Dec 15, 2023 |
| Dec 8, 2023 | RDZN Roadzen Inc. | POpen-market purchase Warrants (right to buy)derivative | +750 | $0.06 | $45 | 750 | Dec 15, 2023 |
| Dec 11, 2023 | RDZN Roadzen Inc. | POpen-market purchase Warrants (right to buy)derivative | +5,000 | $0.05 | $250 | 5,750 | Dec 15, 2023 |
Questions about Supurna VedBrat
Answered from the filings on this page, as of the latest one.
Is Supurna VedBrat buying or selling?
Not in the last 12 months. Supurna VedBrat's latest open-market trade on SEC Form 4 was bought $1,030 of RDZN on Aug 30, 2024.
How did Supurna VedBrat's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Supurna VedBrat has 1.
Where does Supurna VedBrat file Form 4?
Supurna VedBrat has filed Form 4 at RDZN (Roadzen Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.